“…Candidate gene case-control studies identified several putative susceptibility variants associated with AITD development or progression. These included variants in genes encoding proteins related to inflammation, modulation of immune responses, or specific for the thyroid, such as: human leukocyte antigen (HLA) class I and class II, forkhead box P3 (FOXP3), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), cluster of differentiation 40 (CD40), protein tyrosine phosphatase, non-receptor type 22 (PTPN22), selenoprotein S (SEPS1), IL4, IL2 receptor α (IL2RA), VDR, Tg, TSH receptor (TSHR), signal transducer and activator of transcription 3 (STAT3), and STAT4, with HLA-DR3 carrying the highest risk ( 2 , 114 – 120 ). Among non-HLA genes, CTLA4 and PTPN22 were most consistently identified as predisposing to both HT and GD ( 121 – 124 ), while the TSHR locus appears to be specific for GD, but not HT, suggesting some genetic differences between these two types of AITD ( 125 , 126 ); however, similar to PCOS, candidate gene screening for HT susceptibility mainly generated controversial and non-replicable findings ( 127 – 132 ).…”